A randomized phase 3 study comparing cabazitaxel/prednisone in combination with Custirsen (OGX-011) to cabazitaxel/prednisone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer

Administered By

Awarded By

Contributors

Start/End

  • October 1, 2014 - September 30, 2019